Enhanced Treatment of Gastrointestinal Tract Diseases with JAK Inhibitors and Advanced Delivery Systems
Legal Citation
Summary of the Inventive Concept
The present inventive concept provides improved methods and compositions for treating diseases of the gastrointestinal tract using JAK inhibitors, featuring advanced delivery systems that enhance efficacy, safety, and patient compliance.
Background and Problem Solved
The original patent disclosed methods and compositions for treating gastrointestinal tract diseases with JAK inhibitors, but faced limitations in terms of targeted delivery, optimal dosing, and disease marker detection. The new inventive concept addresses these limitations by introducing advanced delivery systems, including ingestible devices, bioadhesive materials, pH-dependent coatings, and temperature-responsive capsules, which enable more precise and effective treatment.
Detailed Description of the Inventive Concept
The inventive concept comprises a system for treating gastrointestinal tract diseases, featuring an ingestible device that releases a pharmaceutical formulation comprising a JAK inhibitor at a predetermined site of disease, equipped with a sensor to detect disease markers and adjust the release of the formulation accordingly. Alternatively, the inventive concept includes a method for treating gastrointestinal tract diseases, comprising orally administering to a subject a pharmaceutical composition comprising a therapeutically effective amount of a JAK inhibitor and a bioadhesive material that enhances retention of the composition at the site of disease. The inventive concept also encompasses a pharmaceutical formulation for treating gastrointestinal tract diseases, comprising a JAK inhibitor and a pH-dependent coating that releases the inhibitor at a predetermined pH range in the gastrointestinal tract. Additionally, the inventive concept includes a device for treating gastrointestinal tract diseases, comprising an ingestible capsule that releases a pharmaceutical formulation comprising a JAK inhibitor in response to a specific temperature range in the gastrointestinal tract. Furthermore, the inventive concept provides a method for monitoring the efficacy of a JAK inhibitor in treating gastrointestinal tract diseases, comprising detecting the concentration of the inhibitor in the plasma of a subject and adjusting the dosage of the inhibitor based on the detected concentration.
Novelty and Inventive Step
The new inventive concept introduces novel and non-obvious advancements over the original patent, including the use of ingestible devices, bioadhesive materials, pH-dependent coatings, and temperature-responsive capsules, which provide targeted and controlled release of JAK inhibitors, thereby enhancing efficacy and reducing side effects. The inventive concept also provides a method for monitoring the efficacy of JAK inhibitors, which enables personalized treatment and optimal dosing.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include the use of different types of sensors, such as optical or acoustic sensors, to detect disease markers. Additionally, the inventive concept may be adapted for use in treating other diseases or conditions, such as inflammatory bowel disease or cancer, by modifying the pharmaceutical formulation or delivery system.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the treatment of gastrointestinal tract diseases, such as Crohn's disease and ulcerative colitis. The advanced delivery systems and personalized treatment approach offered by the inventive concept may improve patient outcomes, reduce healthcare costs, and increase market share for pharmaceutical companies.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/0009 |
| A | A61 | A61K9/0004 |
| A | A61 | A61K9/0053 |
| A | A61 | A61K31/519 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical drug delivery systems, specifically targeted gastrointestinal tract treatments using JAK inhibitors, involving advanced drug formulation and controlled release technologies
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical scientist or biomedical engineer with expertise in drug delivery systems, knowledge of JAK inhibitors, experience with targeted drug release mechanisms, and understanding of gastrointestinal tract pharmacokinetics
Obviousness Rationale
A person having ordinary skill in the art would recognize that the published technical disclosure represents predictable variations on the source patent's core method of JAK inhibitor administration, utilizing known drug delivery techniques to enhance localized treatment and minimize systemic exposure. The proposed modifications represent standard engineering approaches to improving drug delivery that would be apparent to a skilled practitioner seeking to optimize gastrointestinal tract treatments. The variations demonstrate incremental improvements using well-established pharmaceutical engineering principles.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,669 |
|---|---|
| Title | Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices |
| Assignee(s) | Biora Therapeutics, Inc. |